Electrical neurostimulation for the treatment of chronic pruritus: A systematic review

Moustafa Badwy1 | Sara J. Baart1,2 | Hok B. Thio3 | Frank J. P. M. Huygen1 | Cecile C. de Vos1

1Center for pain Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2Department of Biostatistics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
3Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Correspondence
Moustafa Badwy, Center for pain Medicine, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Email: m.badwy@erasmusmc.nl

Abstract
Approximately one fifth of the world population experiences continuous itch for 6 weeks or more during their life, that is chronic itch. It is diverse in its aetiologies, and it is notoriously hard to treat. Because itch and pain have largely overlapping pathophysiology and the demonstrated efficacy of neurostimulation in treatment of selected chronic pain conditions, we conducted a systematic review to investigate whether neurostimulation could be an effective treatment for chronic itch. We identified two randomized controlled trials and 17 open label studies or case reports investigating various neurostimulation modalities for the treatment of refractory itch of various aetiologies. Transcutaneous electrical nerve stimulation (TENS) was the most investigated modality (n = 17), and in the largest number of conditions. Other modalities were cutaneous field stimulation (n = 2), painscrambler (n = 1), transcranial direct current stimulation (n = 1) and peripheral nerve field stimulation (n = 1). Atopic dermatitis was the most studied condition (n = 5). Despite the large heterogeneity in used stimulation paradigms and outcome parameters, all studies reported a positive effect of at least one neurostimulation modality. Our review indicates that electrical neurostimulation could be considered for the treatment of refractory chronic itch of selected aetiologies, such as atopic dermatitis or burn pruritus. However, better understanding of the mechanisms of action of the neurostimulation modalities and regimens in various pruritic conditions is necessary.

KEYWORDS
chronic pruritus, itch, neurostimulation, therapy

1 | INTRODUCTION

Pruritus, or itch, is a common symptom of many conditions, dermatological and otherwise (eg internal, neurological or psychiatric). Most often, treatment of itch is targeted at the causative condition.1,2 In the case of dermatological conditions, topical treatments such as emollients or dermal corticosteroids usually suffice. However, in more severe cases of generalized pruritus, or atopic conditions, treatment with antidepressants, anticonvulsants, biologics, antihistamines or other immune modifiers is not uncommon.1–3 Nonetheless, there is a substantial proportion of patients who do not respond adequately to these modes of treatment.4 If, despite treatment, itch persists for 6 weeks or more, it is considered to be chronic.5
The similarities between the pathophysiology of itch and pain are evident; both sensations are conducted by unmyelinated C and A delta fibres in response to proinflammatory cytokines and tissue injury, and both can induce peripheral and central sensitization as well as respond to psychological factors and treatment with antidepressants, anticonvulsants or biologics. There have been multiple theories as to what constitutes the pathophysiological difference between itch and pain; currently, the most widely supported is the "labelled-line coding theory". However, conclusive evidence does not yet exist.

Various neurostimulation technologies can offer relief for certain intractable chronic pain conditions, which otherwise heavily impact patients’ quality of life. The most commonly used electrical neurostimulation modalities are transcutaneous electrical nerve stimulation (TENS) and spinal cord stimulation (SCS), where the former is performed by the application of external sticker electrodes to the skin, the latter requires the implantation of an electrode lead in the epidural space of the spinal cord. A relative recent invasive method is dorsal root ganglion stimulation (DRGS), where the electrode leads are placed over one or more dorsal root ganglia. Cutaneous field stimulation (CFS) is similar to TENS, with the exception of the presence of small spines on the sticker electrodes, which penetrate into the epidermis (the rationale being that this would lead to better/more direct stimulation of cutaneous nerves). Less commonly used modalities are peripheral nerve field stimulation (PNFS)—where the stimulation electrode is surgically implanted subcutaneously—and transthoracic current stimulation (tDCS)—where electrode-stickers are applied to the cranium directly over the sensorimotor cortices. Research into the mechanisms of action of electrical neurostimulation has provided insight into the pathophysiology of chronic pain and which chronic pain aetiologies are most likely to respond favourably.

By analogy with chronic pain and pain associated with neural damage, there is chronic itch and itch associated with neural damage. An example of the latter is postherpetic itch, in which the nervous system is directly involved. However, in many cases, it is not clear to what extent neural injury contributes to itch, and inversely, to what extent chronic itch might cause neurophysiological alterations. Chronic itch is a frequent condition, with a prevalence of nearly 17%, and limited treatment options. Moreover, itch associated with neural damage responds notoriously bad to conventional treatments.

The primary aim of this study was to investigate the evidence of efficacy of electrical neurostimulation in the treatment of chronic itch conditions. Neurostimulation is not part of standard care for patients with chronic itch at the moment. Addition of a new treatment modality might provide new treatment options for patients suffering from refractory chronic itch. Therefore, the secondary aims of this systematic review are assessing which neurostimulation modalities are most effective and which conditions are most likely to respond favourably.

2 | MATERIALS AND METHODS

We performed a systematic review, adhering to a predefined protocol which we uploaded to the PROSPERO register for systematic reviews (#159112). We assessed the existing evidence of effects of neurostimulation for treatment of chronic itch, the different modes of neurostimulation used and the different itch aetiologies for which neurostimulation was used.

2.1 | Inclusion and exclusion criteria

We defined the following inclusion criteria: reports in English had to be available; study design had to be experimental or quasi-experimental; studies had to concern chronic itch; effects of one or several electrical neurostimulation modalities had to be reported. Furthermore, we defined the following exclusion criteria: studies not pertaining to humans; reports published before 1970; congress abstracts, letters or other non-(quasi)experimental designs; studies investigating experimentally or otherwise induced itch.

2.2 | Search protocol

We performed a structured search action on 7 August 2019 of the following databases: Embase, Medline, Web of Science and google scholar. In the development of a structured search action, we were aided by the Erasmus MC medical library.

2.3 | Study selection

All reports identified with our search action were screened by title and abstract and ambiguous results were discussed until agreement was reached (MB, CV). Duplicates were removed, and of those reports deemed matching above stated eligibility criteria, a full-text version was requested. All full-text reports were read. Those meeting the eligibility criteria were used in data synthesis. We did not perform additional searching.

2.4 | Data extraction

We adapted the standard cochrane data collection form for randomized and non-randomized trials into a customized data-extraction sheet, suitable for both randomized and non-randomized (quasi-) experimental studies.

For each article, we recorded methodological features, itch-related outcomes and other relevant data, for example secondary outcomes and adverse events.

2.5 | Assessment of bias

We performed risk of bias assessment whenever possible, using the latest version of the RoB – 2 for randomized controlled trials and ROBINS for non-randomized controlled trials. For the assessment of uncontrolled trials, we used the revised and validated MINORS criteria, as recommended by Fitzpatrick-Lewis et al."
without a control group, the MINORS criteria consist of eight items (clearly stated aim, inclusion of consecutive patients, prospective collection of data, appropriate endpoints, unbiased assessment, appropriate follow-up period, loss to follow-up <5% and prospective study size calculation). For each of these items, a score of 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate) can be assigned. The highest or best possible MINORS score for uncontrolled trials is thus 16, and the lowest possible score is 0.

We used a tool developed by Murad et al. for the assessment of methodological quality of case reports and case series. This tool consists of eight items divided over four categories (selection of patients, ascertainment of exposure and outcome, causality and reporting). For each item, a score is attributed of 0 (inadequate) or 1 (adequate). The highest, or best possible score for case reports and case series is thus 8, and the lowest possible score is 0. We did not use additional sources (next to the reports themselves) to perform risk of bias analysis, or assessment of methodological quality.

2.6 | Outcome measures

We used outcome measures that indicated the effect of neurostimulation on short-term and long-term itch intensity in our data synthesis, for example visual analogue scale (VAS) or numeric rating scale (NRS). Secondary outcome measures were the different modalities and protocols of neurostimulation used and the different aetiologies of itch for which these were used.

If possible, we used relevant summary statistics to represent results; otherwise, we used narrative data synthesis.

3 | RESULTS

Of the 1608 reports that we identified, 37 met our eligibility criteria. Of these 37 reports, 13 were excluded because they were duplicates or because there was no full-text version available. After full-text screening of the remaining 24 reports, another five were excluded because they concerned experimentally or otherwise induced itch, because they primarily concerned pain, or because they were a letter to the editor (Figure 1).

Nineteen studies were included: two randomized controlled trials (RCT), ten uncontrolled trials, one case series and six case reports.

All studies reported a positive effect of at least one modality of electrical neurostimulation on itch. There was, however, large heterogeneity in methodological set-up and how the effect on pruritus of various aetiologies was measured.

3.1 | Conditions and diseases

All but one report specified one or more itch conditions for which neurostimulation was used. One report described the conditions as “diverse.” In total, twenty different itch conditions were reported on. Most studies reported on a single condition (n = 13), while six studies reported on pruritic conditions of multiple aetiologies (Table 1). The condition most frequently investigated, was atopic eczema/atopic dermatitis, by five studies (one trial and four case reports/series). Generalized or senile pruritus, burn pruritus, lichen simplex and notalgia paresthetica were each investigated by three different studies. Table 1 gives a full overview of the different conditions investigated in each study.

FIGURE 1 Flowchart of study selection. † Congress abstracts (N = 6, Bruel 2013, Lang 2013, Ricciardo 2009, Orthman 2019, Carroll 2009). Only abstract available (N = 3, Fjellner 1978, Kilic Akca 2016, Duo 1987). Only title available (N = 1, Sequeira 2016). Duplicate (N = 2, Wallengren 2004, Waked 2013). Erratum (latest version used) (N = 1, Yusek 2013). ‡ Experimentally induced itch (N = 3, Hill 2015, Nilsson 1996, Wallengren 2002). Primarily concerning pain (N = 1, Wang 2009). Letter to editor (N = 1, Tinegate 2002)
3.2 | Neurostimulation modality and stimulation regimen

The included reports studied four different neurostimulation modalities. The majority evaluated the effect of TENS on itch (n = 15). The stimulation regimens that were used in these studies, however, were highly variable and are summarized in Table 2.

Duration of treatment varied from a single session of 25 min to 2 years; however, most studies had a treatment duration of one to 4 weeks. Similarly, frequency of treatment varied from three times per day to three times per week, with sessions ranging from 20 min to 1 h (Table 2). Several studies did not report frequency and/or session time. In one study, this was because the stimulation was at the patient’s discretion.

The location of stimulation differed between studies and partly depended on the studied condition(s). Almost all the studies concerning localized conditions applied stimulation to the affected or most pruritic area. For generalization purposes, the place of stimulation was variable. Not all studies reported the stimulation settings of the device they used (eg frequency, amplitude).

Two studies evaluated the effect of CFS on itch. One was a randomized controlled trial that compared the effect of CFS with the effect of TENS. Furthermore, we identified studies that evaluated the effect of painscrambler therapy, tDCS, and PNFS (Table 1).

3.3 | Outcome measures

The most frequently used primary outcome measure to assess the effect of neurostimulation on itch was self-reported VAS for itch intensity (n = 11). Several studies used outcome measures comparable to VAS, such as NRS for itch (n = 2) or itch intensity measured on a predefined numerical scale (n = 1). The remaining five studies did not report itch intensity on any numerical scale or measure, but used descriptive itch intensity relative to baseline. None of the studies mentioned explicitly whether itch measurements applied to discrete time points or to time intervals.

Furthermore, most studies reported on secondary outcomes as well, for example quality of sleep (n = 4), multi-dimensional itch instruments (5-D itch scale and Leuven itch scale, which quantify the impact of itch on multiple life domains, n = 1), pain (n = 1) or dermatological outcome measures (n = 6). Lastly, eight studies also reported the occurrence of adverse events as a secondary outcome measure.

The time points at which outcomes were measured varied greatly among studies. Whereas most trials had discrete, predefined time points at which measurements were performed, nearly all case-reports lacked these. Table 1 gives an overview of primary outcome measures, and Table 2 gives an overview of the duration of the studies.

3.4 | TENS

All but one of the studies that investigated the effect of TENS on itch found a positive effect. A randomized controlled trial comparing TENS with CFS found that TENS had no significant effect on itch intensity in patients with atopic dermatitis; the overall risk of bias in this study was high, due to a high risk of bias in, among others, the domains of measurement of outcome and selection of reported result.

Positive effect of TENS was reported by nine trials, one of which was an RCT. This randomized controlled pilot study with 30 patients investigated the effect of TENS in patients with burn pruritus. VAS score for itch decreased significantly in the TENS group over 3 weeks of treatment and did not in the control group, who received conventional treatment. Overall risk of bias, however, was high, due to a high risk of bias in, among others, the domains of randomization and selection of reported result.

Furthermore, eight uncontrolled trials, four case reports, and one case series found a positive effect of TENS on itch intensity. Outcomes of studies investigating TENS are presented in Table 3, and methodological quality/risk of bias assessment are presented in Table 1.

Eight studies aimed to investigate the occurrence of adverse events. One trial with 22 patients with lichen simplex reported a single occurrence of mild erythema during treatment. Another trial with 46 patients with diverse conditions reported eight cases of mild numbness and irritation and 6 cases of mild erythema, all of which were reversible. One trial reported an increase in itch intensity during the application of TENS, though this increased itch did not persist afterwards. Two trials and two case reports also reported improvement in quality of sleep, and three trials reported an improvement in quality of life.

3.5 | CFS

We identified two trials concerning CFS: an RCT and a trial without a control group. In these trials, 15 patients with atopic dermatitis and 19 patients with diverse conditions were treated with CFS, respectively. Both trials identified a positive effect of CFS on itch. Nilsson et al. found a significant reduction in VAS for itch, lasting up to 7 h after treatment. The risk of bias of this study was high (Table 1). Wallengren et al. found a significant reduction of VAS for itch, at 1–5 weeks of treatment. The methodological quality of this study was assessed using the MINORS criteria, scoring 8 out of 16. Neither of these studies reported on the occurrence of adverse events.

3.6 | Painscrambler

We identified one uncontrolled trial with 16 patients using painscrambler therapy. This modality is similar to TENS; however, it uses different electrical settings, aimed at specifically stimulating C-fibres. This trial reported a significant reduction in NRS for itch after both 5 and 10 days of follow-up. Furthermore, a significant improvement in both 5-D itch scale and Leuven itch scale was noted. Occurrence of adverse events was not reported. The methodological quality of this study was assessed using the MINORS criteria, scoring 12 out of 16.
| Study ID       | Study type | Neuromodulation | Number of patients | Conditions                                                                 | Primary outcome | Risk of bias/quality a |
|---------------|------------|-----------------|--------------------|----------------------------------------------------------------------------|-----------------|------------------------|
| Hettrick (2004) | Pilot-RCT  | TENS            | 30                 | Burn pruritus                                                             | VAS for itch    | RoB-2: High risk of bias |
| Nilsson (2004) | RCT        | CFS, TENS       | 35                 | Atopic dermatitis                                                         | VAS for itch    | RoB-2: High risk of bias |
| Bicer (2003)   | Trial      | TENS            | 15                 | Generalized pruritus                                                      | VAS for itch    | MINORS: 8               |
| Engin (2009)   | Trial      | TENS            | 22                 | Lichen simplex                                                            | VAS for itch    | MINORS: 10              |
| Joo (2017)     | Trial      | Painscrambler   | 16                 | Burn pruritus                                                             | NRS for itch    | MINORS: 12              |
| Lyon (1998)    | Trial      | TENS            | 24                 | Psoriasis \(n = 12\), eczema \(n = 7\), lichen planus \(n = 1\), mycosis fungoides \(n = 1\), pemphigoid \(n = 1\), pruritus vulvae \(n = 1\), senile/idiopathic pruritus \(n = 1\) | VAS for itch    | MINORS: 8               |
| Mohammad (2019)| Trial      | TENS            | 46                 | Atopic dermatitis \(n = 10\), lichen simplex chronicus \(n = 20\), chronic liver disease \(n = 16\) | VAS for itch    | MINORS: 10              |
| Savk (2007)    | Trial      | TENS            | 15                 | Notalgia paraesthetica                                                    | NRS for Itch    | MINORS: 10              |
| Tang (1999)    | Trial      | TENS            | 5                  | Neurodermatitis \(n = 1\)                                                | VAS for Itch    | MINORS: 12              |
| Waked (2019)   | Trial      | TENS            | 33                 | Lichen planus                                                             | VAS for itch    | MINORS: 10              |
| Wallengren (2001)| Trial   | CFS             | 19                 | Brachioradial pruritus \(n = 9\), mycosis fungoides \(n = 1\), neurodermatitis \(n = 1\), notalgia paraesthetica \(n = 5\), meralgia paraesthetica \(n = 1\) | VAS for itch    | MINORS: 8               |
| Yusek (2011)   | Trial      | TENS            | 16                 | Macular amyloidosis \(n = 8\), lichen simplex \(n = 8\)               | VAS for itch    | MINORS: 10              |
| Bjorna (1987)  | Case report| TENS            | 1                  | Atopic eczema                                                             | Itch intensity on 6-point scale | Murad: 7               |
| Carlsson (1975)| Case series| TENS            | 17                 | Diverse (not further specified)                                           | Itch intensity (not further specified) | Murad: 2               |
| Chan (2000)    | Case report| TENS            | 2                  | Reactive perforating collagenosis                                          | Itch intensity (not further specified) | Murad: 4               |
| Knotkova (2013)| Case report| tDCS            | 1                  | Syringomyelia                                                             | Itch intensity (relative to baseline) | Murad: 8               |
| Monk (1993)    | Case report| TENS            | 2                  | Generalized pruritus                                                      | Itch intensity (not further specified) | Murad: 5               |
| Ricciardo (2010)| Case report| PNFS            | 1                  | Notalgia paraesthetica                                                   | Itch intensity (not further specified) | Murad: 2               |
| Whitaker (2001)| Case report| TENS            | 1                  | Burn pruritus                                                             | VAS for itch    | Murad: 6                |

Abbreviations: CFS, Cutaneous Field Stimulation; NRS, Numerical Rating Scale; PNFS, Peripheral Nerve Field Stimulation; tDCS, transcranial Direct Current Stimulation; TENS, Transcutaneous Electrical Nerve Stimulation; VAS, Visual Analog Scale.

*RoB-2 for RCT’s: high, medium or low risk of bias; MINORS for uncontrolled trials (worst – best): 0–16; Murad et al. for case reports and case series (worst – best): 0–8.
We identified one case report on tDCS in a patient suffering from syringomyelia. The patient reported a 50–60% improvement in itch intensity, relative to baseline, which lasted up to 3 months after treatment. NRS for pain was reported as well, since treatment was originally intended for neuropathic pain. Pain was, however, not affected by the treatment. Occurrence of adverse events was not reported. The methodological quality of this case report was assessed using the tool by Murad et al., scoring 6 out of 8.

We identified one case report applying PNFS to a 60-year-old woman with intractable notalgia paresthetica. Postimplantation of the subcutaneous PNFS electrode, the patient described an 85% reduction of itch intensity, compared to baseline. This effect was maintained for at least 5 months. Occurrence of adverse events was not reported. The authors concluded that PNFS is a possible treatment for unresponsive notalgia paraesthetica. The methodological quality of this case report was assessed using the tool by Murad et al., scoring 2 out of 8.
| Study ID | Outcome | Time points for evaluation | Reported as | Result | p-value | Adverse events |
|----------|---------|---------------------------|-------------|--------|---------|----------------|
| Hettrick (2004) | VAS for itch | Daily | Slope | TENS: -3.51 | <0.02 | - |
| Nilsson (2004) | VAS for itch | 8 measurements up to 12 h after treatment | Description<sup>b</sup> | During treatment: +409% | No significant reduction in VAS for itch up to 12 h after treatment | <0.01 | - |
| Bicer (2003) | VAS for itch | 3, 7, 15 and 21 days after start of treatment | Slope | Day 3: 7.13 Day 7: 5.0 Day 15 3.93 Day 21: 2.93 | <0.001 | No |
| Engin (2009) | VAS for itch | 1 and 2 months after start of treatment | Difference | Baseline: 7 1 month: 2.5 2 months: 2.54 | NA | Yes |
| Lyon (1998) | VAS for itch | 7 days after start of treatment | % reduction | 35.4% | <0.05 | No |
| Mohammad (2015) | VAS for itch | 2 weeks, 1 and 2 months after start of treatment | Difference | Baseline AD: 7.1; LSC: 7.7; CLD: 7.1 2 weeks AD: 4.5; LSC: 4.9; CLD: 4.8 1 month AD: 1.8; LSC 2.5; CLD: 2.8. 2 months AD: 2.7; LSC 3.3; CLD: 4.0. | NA | Yes |
| Savk (2007) | NRS for Itch | 1 and 2 weeks after start of treatment | Difference | 1 week: 7.67 2 weeks: 6.8 | <0.05 | No |
| Tang (1999) | VAS for itch | Daily measurements for 7 days | Mean | Day 1: 7 Day 2: 5 Day 3: 5 Day 4: 4 Day 5: 4 Day 6: 4 Day 7: 4 | NR | No |
| Waked (2019) | VAS for itch | 2 and 4 weeks after start of treatment | Difference | Baseline: 8.3 2 weeks: 5.63 4 weeks: 2.13 | NA | No |
| Yusek (2011) | VAS for itch | 2 and 4 weeks after start of treatment | Difference | Baseline: 8 2 weeks: 4 4 weeks: 2 | NA | - |
| Bjorna (1987) | Itch intensity on 6-point scale | Daily measurements for 8 months | Modus | Baseline: 4 1–4th month: 1 4–5th month: 2 6th month: 1 7–8th month: 0 | NA | - |
| Carlsson (1975) | Itch intensity (not further specified) | Not reported | Description<sup>b</sup> | "14 out of 17 patients experienced considerable alleviation of itch." | NA | - |
| Chan (2000) | Itch intensity (not further specified) | Not reported | Description<sup>b</sup> | "Both patients experienced substantial relief of itch." | NA | No |
| Monk (1993) | Itch intensity (not further specified) | Not reported | Description<sup>b</sup> | Abolition of itch after several sessions; one patient reported prolonged itch reduction. | NA | - |

(Continues)
3.9 Secondary results

Several studies reported dermatological, pathological or biochemical parameters as secondary results. A trial investigating TENS reported a significant healing effect in only a minority of patients (8 out of 22).\(^4\) Another trial of 33 patients with TENS reported a significant improvement in Dermatological Quality of Life Index (DQLI) \((p < 0.001)\) after 2 weeks of treatment.\(^5\) A similar finding was reported in a study investigating TENS in patients with macular amyloidosis and lichen simplex, both groups showed a significant improvement in DQLI after 2 weeks of treatment \((p = 0.001, p = 0.006, \text{resp.})\).\(^6\) A case report concerning a patient with atopic dermatitis furthermore reported influence of TENS on plasma levels of adrenocorticotrophic hormone (ACTH) and vasoactive intestinal peptide (VIP) as markers for inflammation and disease activity, as well as rise in skin temperature and clinical improvement of lesions.\(^7\) One study investigating the effect of CFS in patients notalgia paraesthetica and brachioradial pruritus used skin biopsies to determine the density of cutaneous nerve fibres. No significant alteration in nerve fibre density was observed, however.\(^8\)

4 DISCUSSION

There is evidence that certain electrical neurostimulation modalities can effectively treat refractory chronic itch. However, the studies we identified were mostly of low methodological quality or provided merely a low level of evidence (eg case reports). All studies reported a positive effect of at least one neurostimulation modality on chronic itch, but neurostimulation modalities and causes of itch varied largely. We therefore conclude that although there are indications that neurostimulation can be an effective treatment for chronic itch of selected aetiologies, additional research is needed to further optimize and establish neurostimulation as a treatment for chronic itch.

We found notably more studies relating to the effect of TENS than to any other neurostimulation modality. Though the evidence suggesting a positive effect of TENS in the treatment of chronic itch is stronger and more abundant, even the largest trials we identified had several methodological drawbacks. Furthermore, among the two studies supplying the highest level of evidence, there was no consensus regarding the effectiveness of TENS. This could be due to the high variety in stimulation regimens that were used (eg duration, frequency and settings). None of the studies provided justification or explanation for the specific regimens that were used. Regarding the other modes of neurostimulation we identified (PNFS, pain-scrambler, CFS and tDCS), there are only tentative indications of positive effects. CFS was second most studied, by two trials, one of which was an RCT. However, analogous to TENS, there were similar methodological drawbacks to both studies.

The most prominent limitations of our systematic review are the limited number of large, methodologically sound studies and that the conducted studies showed large heterogeneity with regard to duration, stimulation regimen and the moments at which the effect of stimulation was assessed. It was therefore not feasible to perform a meta-analysis. The fact that all the studies we identified reported a positive effect of at least one neurostimulation modality might also in part be due to publication bias.

5 MAJOR OPEN QUESTIONS

Though our systematic review provides an indication that electrical neurostimulation is beneficial for certain patients suffering from chronic itch, several points require further research. As mentioned, there is a lack of large, methodologically sound trials. In order to further establish the efficacy of modalities such as TENS for the treatment of chronic itch, such trials are imperative. Furthermore, based on the current evidence, it is not possible to recommend a specific stimulation regimen. Different regimens need to be compared in a systematic and prospective fashion.

The itch conditions for which TENS and other electrical neurostimulation modalities were applied were very diverse, ranging from common conditions such as atopic dermatitis, to rarer ones, as for instance notalgia paraesthetica. However, all studied itch conditions concerned localized dermatologic or neuropathic itch conditions. For generalized itch or systemic itch, we did not find evidence, which suggests that their treatment with neurostimulation possibly has to be more invasive to target more central structures. Based on the current evidence, it is not possible to reliably predict the response to a specific neurostimulation treatment for the various itch conditions. All the investigated conditions responded to at least one neurostimulation modality, even though most did not have a clear neuropathic
origin, but were rather chronic pruritic dermatoses. This observation underlines the necessity of further research into the neurophysiology and pathophysiology of various chronic itch conditions and the working mechanisms of neurostimulation in chronic itch.

6 CONCLUSIONS AND PERSPECTIVES

Our review indicates that neurostimulation (especially TENS) can be considered as a treatment option for patients with intractable pruritus. Furthermore, the beneficial effect of electrical neurostimulation in pruritic dermatoses such as atopic dermatitis provides an indication (albeit circumstantial) that there is a neurogenic component in the pathophysiology of these conditions that can be targeted.

The use of electrical neurostimulation has proved to be a useful option in the treatment of chronic pain. Future research will have to further establish and optimize the role of electrical neurostimulation in the treatment of chronic itch. Though the analogy to pain would suggest that neurostimulation should be of great use to those pruritic conditions that involve direct damage to the nervous system, our study shows that neurostimulation might very well have a wider use, including primary pruritic dermatoses.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST

All authors declare they have no affiliations with or involvement in any organization or entity with any financial interests, or non-financial interests in the subject matter or materials discussed in this manuscript.

AUTHOR CONTRIBUTIONS

The conception originated from C.C. de Vos. The protocol was written by M. Badwy. Articles were selected by M. Badwy and C.C. de Vos. Subsequent data extraction and analysis was performed by M. Badwy, S.J. Baart and C.C. de Vos. The first draft was written by M. Badwy, and further input was provided by H.B. Thio, F.J.P.M. Huysgen and C.C. de Vos.

ORCID

Moustafa Badwy https://orcid.org/0000-0001-7705-0960
Cecile C. de Vos https://orcid.org/0000-0001-7210-1693

REFERENCES

1. Nowak DA, Yeung J. Diagnosis and treatment of pruritus. Can Fam Physician. 2017;63:918-924.
2. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet. 2003;361:690-694.
3. Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142:1375-1390.
4. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368:1625-1634.
5. Ständer S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology. 2010;221:229-235.
6. van Laarhoven AIM, Marker JB, Elberling J, et al. Itch sensitization? A systematic review of studies using quantitative sensory testing in patients with chronic itch. Pain. 2019;160:2661-2678.
7. Ikoma A, Rukwied R, Ständer S, et al. Neuropathology of pruritus: interaction of itch and pain. Arch Dermatol. 2003;139:1475-1478.
8. Namer B, Carr R, Johanek LM, et al. Separate peripheral pathways for pruritus in man. J Neuropsychiatry. 2008;10:2062-2069.
9. Dong X, Dong X. Peripheral and central mechanisms of itch. Neuron. 2018;98:482-494.
10. Hofmeister M, Memedovich A, Brown S, et al. Effectiveness of neurostimulation technologies for the management of chronic pain: a systematic review. Neuromodulation. 2020;23:150-157.
11. Zhang JM, Li H, Munir MA. Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine. Pain. 2004;109:143-149.
12. Jones KL, Finn DP, Governo RJ, et al. Identification of discrete sites of action of chronic treatment with desipramine in a model of neuropathic pain. Neuropharmacology. 2009;56:405-413.
13. Arle JE, Mei L, Carlson KW, et al. High-frequency stimulation of dorsal column axons: potential underlying mechanism of paresthesia-free neuropathic pain relief. Neuromodulation. 2016;19:385-397.
14. de Vos CC, Mei K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155:2426-2431.
15. Kriek N, Schreurs MWJ, Groeneweg JG, et al. Spinal cord stimulation for complex regional pain syndrome: a possible target for immunomodulation? Neuromodulation. 2018;21:77-86.
16. Ishikawa R, Iseki M, Koga R, et al. Investigation of the correlation between postherpetic itch and neuropathic pain over time. Pain Res Manag. 2018;2018:9305126.
17. (EPOC) CEPaOoC. Effective Practice and Organisation of Care (EPOC). Data collection form. epoc.cochrane.org/epoc-resources-review-authors. Accessed January 22, 2020; 2017.
18. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
19. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
20. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors); development and validation of a new instrument. ANZ J Surg. 2003;73:712-716.
21. Fitzpatrick-Lewis D, Ciliska D, Thomas H. The methods for the synthesis of studies without control groups. 2009.
22. Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60-63.
23. Bruel B, Engle M. Chronic itching: a novel indication for spinal cord stimulation. Neuromodulation. 2013;16:e73.
24. Lang M, Treister R, Klein M, et al. A pilot study of efficacy of repetitive transcranial magnetic stimulation (rTMS) of the motor cortex on neuro itch. Acta Derm Venereol. 2013;93:617-618.
25. Ricciardo B, Kumar S, O’Callaghan J, et al. Peripheral nerve field stimulation for pruritus relief in a patient with notalgia paresthetica. Australas J Dermatol. 2009;50:A38.
26. Ohrman E, Thibaut A, Morales-Quezada L, et al. Effects of transcranial direct current stimulation on pain and itch after burn injury. J Burn Care Res. 2019;40:S180.
27. Carroll I, Wang C. Treatment of notalgia paresthetica with direct electrical stimulation of serratius anterior muscle. J Pain. 2009;10:S61.
28. Fjellner B, Hagermark O. Transcutaneous nerve stimulation and itching. Acta Derm Venereol. 1978;58:131-134.
29. Kılıç Akça N, Taşçi S. Acupressure and transcutaneous electrical acupuncture stimulation for improving uremic pruritus: a randomized controlled trial. *Altern Ther Health Med.* 2016;22:18-24.

30. Duo LJ. Electrical needle therapy of uremic pruritus. *Nephron.* 1987;47:179-183.

31. Sequeira J, Pereira D, Rainho C. Pruritic hyperpigmented patch on back. *J Fam Pract.* 2016;65:591-596.

32. Wallengren J. Cutaneous nerve stimulation in treatment of localized itch. In: G. Yosipovitch, M. Greaves, A. Fleischer, F. McGlone eds. *Itch Basic Mechanisms and Therapy.* New York: Marcel Dekker, Inc.; 2004. p.335-342.

33. Waked IS, Nagib SH, Ashm HN. Triamcinolone acetonide pho- phoresis versus transcutaneous electrical nerve stimulation in the treatment of post-burn pruritus: A randomised controlled study. *Indian J Physiother Occup Ther Int J.* 2013;7(2):92.

34. Yüksel S, Sezer E, Aksu M, et al. Transcutaneous electrical nerve stimulation for reduction of pruritus in macular amyloidosis and lichen simplex. *J Dermatol.* 2011;38:546-552.

35. Hill AJ, Paraiso MFR. Resolution of chronic vulvar pruritus with electrical nerve stimulation. *J Minimally Invasive Gynecol.* 2015;22:889-891.

36. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. *Pain.* 1997;71:49-55.

37. Wallengren J. Cutaneous field stimulation of sensory nerve fibers reduces itch without affecting contact dermatitis. *Allergy Eur J Allergy Clin Immunol.* 2002;57:1195-1199.

38. Wang CK, Gowda A, Barad M, et al. Serratus muscle stimulation effectively treats notalgia paresthetica caused by long thoracic nerve dysfunction: a case series. *J Brachial Plex Peripher Nerve Inj.* 2009;4:17.

39. Tinegate H, McLelland J. Transcutaneous electrical nerve stimulation may improve pruritus associated with haematological disorders. *Clin Lab Haematol.* 2002;24:389-390.

40. Hettrick H, O’Brien K, Laznick H, et al. Effect of transcutaneous electrical nerve stimulation for the management of burn pruritus: a pilot study. *J Burn Care Rehabil.* 2004;25:236-240.

41. Nilsson HJ, Psouni E, Carstam R, et al. Profound inhibition of chronic itch induced by stimulation of thin cutaneous nerve fibres. *J Eur Acad Dermatol Venereol.* 2004;18:37-43.

42. Bicjer A, Baz K, Tursen U, et al. High frequency transcutaneous electrical nerve stimulation treatment in patients with generalized pruritus. *Gazi Med J.* 2003;14:67-70.

43. Engin B, Tufekci O, Yazici A, et al. The effect of transcutaneous electrical nerve stimulation in the treatment of lichen simplex: a prospective study. *Clin Exp Dermatol.* 2009;34:324-328.

44. Joo SY, Cho YS, Cho SR, et al. Effects of pain scrambler therapy for management of burn scar pruritus: a pilot study. *Burns.* 2017;43:514-519.

45. Lyon CC, Howlett N, Harrison PV. The effects of transcutaneous nerve stimulation on pruritus in dermatological patients. *J Dermatol Treat.* 1998;9:21-23.

46. Mohammad Ali BM, Hegab DS, El Saadany HM. Use of transcutaneous electrical nerve stimulation for chronic pruritus. *Dermatol Ther.* 2015;28:210-215.

47. Şavk E, Şavk Ö, Şendur F. Transcutaneous electrical nerve stimulation offers partial relief in notalgia paresthetica patients with a relevant spinal pathology. *J Dermatol.* 2007;34:315-319.

48. Tang WYM, Chan LY, Lo KK, et al. Evaluation on the antipruritic role of transcutaneous electrical nerve stimulation in the treatment of pruritic dermatoses. *Dermatology.* 1999;199:237-241.

49. Waked I, Ibrahim Z, Elghary HMI. Does transcutaneous electrical nerve stimulation have an antipruritic effect in lichen planus? A randomized clinical trial. *Clin Exp Dermatol.* 2019;44:252-256.

50. Wallengren J, Sundler F. Cutaneous field stimulation in the treatment of severe itch. *Arch Dermatol.* 2001;137:1323-1325.

51. Yuksel S, Sezer E, Aksu M, et al. Transcutaneous electrical nerve stimulation for reduction of pruritus in macular amyloidosis and lichen simplex (vol 38, pg 546, 2011). *J Dermatol.* 2013;40:86-.

52. Carlsson CA, Augustinsson LE, Lund S, et al. Electrical transcutaneous nerve stimulation for relief of itch. *Experiencia.* 1975;31:191.

53. Bjorna H, Kaada B. Successful treatment of itching and atopic eczema by transcutaneous nerve stimulation. *Acupunct Electro-Ther Res.* 1987;12:101-112.

54. Chan LY, Tang WYM, Lo KK. Treatment of pruritis of reactive perforating collagenosis using transcutaneous electrical nerve stimulation. *Eur J Dermatol.* 2000;10:59-61.

55. Knotkova H, Portenoy RK, Cruciani RA. Transcranial direct current stimulation (tDCS) relieved itching in a patient with chronic neuropathic pain. *Clin J Pain.* 2013;29:621-622.

56. Monk BE. Transcutaneous electronic nerve stimulation in the treatment of generalized pruritus. *Clin Exp Dermatol.* 1993;18:67-68.

57. Ricciardo B, Kumar S, O’Callaghan J, et al. Peripheral nerve field stimulation for pruritus relief in a patient with notalgia paraesthetica. *Australas J Dermatol.* 2010;51:56-59.

58. Whitaker C. The use of TENS for pruritus relief in the burns patient: an individual case report. *J Burn Care Rehabil.* 2001;22:274-276.

59. Marineo G. Inside the scrambler therapy, a noninvasive treatment of chronic neuropathic and cancer pain: from the gate control theory to the active principle of information. *Integr Cancer Ther.* 2019;18:1534735419845143.

How to cite this article: Badwy M, Baart SJ, Thio HB, Huygen FJP, de Vos CC. Electrical neurostimulation for the treatment of chronic pruritus: A systematic review. *Exp Dermatol.* 2022;31:280-289. [https://doi.org/10.1111/exd.14468](https://doi.org/10.1111/exd.14468)